Back

Protein Structure Inspired Drug Discovery

Qiao, F.; Binkowski, A.; Broughan, I.; Chen, W.; Natarajan, A.; Schiltz, G.; Scheidt, K.; Anderson, W.; Bergan, R.

2024-05-20 cancer biology
10.1101/2024.05.17.594634 bioRxiv
Show abstract

Drug discovery starts with known function, either of a compound or a protein, in-turn prompting investigations to probe 3D structure of the compound-protein interface. As protein structure determines function, we hypothesized that unique 3D structural motifs represent primary information denoting unique function that can drive discovery of novel agents. Using a physics-based protein structure analysis platform developed by us, designed to conduct computationally intensive analysis at supercomputing speeds, we probed a high-resolution protein x-ray crystallographic library developed by us. We selected 3D structural motifs whose function was not otherwise established, that offered environments supporting binding of drug-like chemicals and were present on proteins that were not established therapeutic targets. For each of eight potential binding pockets on six different proteins we accessed a 60 million compound library and used our analysis platform to evaluate binding. Using eight-day colony formation assays acquired compounds were screened for efficacy against human breast, prostate, colon and lung cancer cells and toxicity against human bone marrow stem cells. Compounds selectively inhibiting cancer growth segregated to two pockets on separate proteins. The compound, Dxr2-017, exhibited selective activity against human melanoma cells in the NCI-60 cell line screen, had an IC50 of 19 nM against human melanoma M14 cells in our eight-day assay, while over 2100-fold higher concentrations inhibited stem cells by less than 30%. We show that Dxr2-017 induces anoikis, a unique form of programmed cell death in need of targeted therapeutics. The predicted target protein for Dxr2-017 is expressed in bacteria, not in humans. This supports our strategy of focusing on unique 3D structural motifs. It is known that functionally important 3D structures are evolutionarily conserved. Here we demonstrate proof-of-concept that protein structure represents high value primary data to support discovery of novel therapeutics. This approach is widely applicable. Author summaryWe introduce the concept that protein 3D structure represents primary information which can support downstream investigations, in this instance leading to the discovery of novel anticancer therapeutics.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Molecules
39 papers in training set
Top 0.1%
22.4%
2
PLOS ONE
5266 papers in training set
Top 21%
8.1%
3
International Journal of Molecular Sciences
494 papers in training set
Top 0.6%
7.4%
4
ACS Omega
105 papers in training set
Top 0.1%
6.4%
5
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.1%
4.4%
6
ACS Medicinal Chemistry Letters
17 papers in training set
Top 0.1%
4.1%
50% of probability mass above
7
Scientific Reports
3612 papers in training set
Top 32%
3.3%
8
ACS Chemical Biology
167 papers in training set
Top 0.8%
3.3%
9
Pharmaceuticals
34 papers in training set
Top 0.2%
2.5%
10
Biomedicine & Pharmacotherapy
42 papers in training set
Top 0.5%
2.0%
11
Computers in Biology and Medicine
128 papers in training set
Top 2%
2.0%
12
Biochemistry and Biophysics Reports
30 papers in training set
Top 0.4%
1.7%
13
Biochemical Pharmacology
20 papers in training set
Top 0.2%
1.7%
14
Journal of Chemical Information and Modeling
238 papers in training set
Top 2%
1.5%
15
ChemBioChem
55 papers in training set
Top 0.7%
1.5%
16
European Journal of Medicinal Chemistry
17 papers in training set
Top 0.2%
1.4%
17
PLOS Computational Biology
1863 papers in training set
Top 17%
1.2%
18
Journal of Medicinal Chemistry
77 papers in training set
Top 0.7%
1.2%
19
Computational and Structural Biotechnology Journal
242 papers in training set
Top 5%
1.1%
20
ChemMedChem
16 papers in training set
Top 0.3%
1.0%
21
RSC Advances
22 papers in training set
Top 0.7%
1.0%
22
Pharmacology Research & Perspectives
11 papers in training set
Top 0.3%
0.9%
23
Molecular Cancer Therapeutics
40 papers in training set
Top 0.8%
0.9%
24
Biochemical Journal
91 papers in training set
Top 1%
0.9%
25
Chemistry – A European Journal
14 papers in training set
Top 0.2%
0.9%
26
Angewandte Chemie International Edition
93 papers in training set
Top 2%
0.6%
27
Chemical Research in Toxicology
10 papers in training set
Top 0.4%
0.6%
28
Cancers
213 papers in training set
Top 5%
0.6%
29
Bioorganic & Medicinal Chemistry Letters
10 papers in training set
Top 0.2%
0.6%